What bleeding risk is highlighted for patients with haemophilia A or B receiving darunavir as a protease inhibitor?

Patients with haemophilia A or B receiving darunavir should be warned of possible increased bleeding, including spontaneous skin haematomas and haemarthrosis, reported with protease inhibitors; a causal relationship is suggested, but the mechanism is unknown.